Business
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
"In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income2 margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of
About this update from Fresenius Medical Care Ag
[{"type":"list","items":[{"val":[{"type":"text","content":"Strong organic revenue growth1 of 10% driven by all operating segments","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive U.S. same market treatment growth of 0.1 % in line with expectations","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7%","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"Reported operating income grew by 3%, reported net income3 by 29%","length":65,"tagName":"p"}]},{"val":[{"type":"text","content":"Net leverage ratio further improved to 2.6x, in parallel to share buyback and Value-Based Care investments","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"FY 2025 outlook confirmed","length":25,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":462,"olType":false},{"type":"text","content":"BAD HOMBURG, Germany, Nov. 4, 2025 /PRNewswire/ -- "In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income2 margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook", said Helen Giza, Chief Executive Officer of Fresenius Medical Care AG. "All three operating segments contributed to the Group organic growth of 10%. U.S. same market treatment growth was slightly positive in Q3. Operating income2 in Care Enablement grew strongly by 38%, leading to a margin of 7.6%. In parallel, Care Delivery significantly improved profitability, reaching a strong margin of 14.5%, at the top end of its 2025 target margin band." Helen Giza added: "We advanced our FME Reignite strategy for value creation with the launch of the first tranche of our initial share buyback program, the ownership increase in our Value-Based Care entity Interwell Health and the continued rollout of the 5008X in the U.S. For 2025, we are well on track to achieve our commitments, while we are excited about what lies ahead with FME Reignite."","length":1390,"tagName":"p"},{"type...